Soluble Interleukin-2 Receptor Levels in Cytomegalovirus Disease and Graft Versus Host Disease after T-Lymphocyte Depleted Bone Marrow Transplantation for Hematological Neoplasias

References

• Kelso A. Cytokines: structure, function and synthesis. Current Opinion in Immunol. 1989; 2(2)215
   PubMed Web of Science ®Google Scholar
• Paul W. Pleiotropy and redundancy: T Cell-derived lymphokines in the immune response. Cell 1989; 57: 521
   PubMed Web of Science ®Google Scholar
• Loughnan M.S., Nossal G.J.V. Interleukins 4 and 5 control expression of IL-2 receptor on murine B cells through independent induction of its two chains. Nature 1989; 340: 76
   PubMed Web of Science ®Google Scholar
• Hatakeyama M., Tsudo M., Minamoto S., Kono T., Doi T., Miyata M., Miyasak T., Taniguchi T. Interleukin-2 receptor beta-chain gene; generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science 1989; 244: 551
   PubMed Web of Science ®Google Scholar
• Crabtree G.R. Contingent genetic regulatory events in T lymphocyte activation. Science 1989; 243: 355
   PubMed Web of Science ®Google Scholar
• Rubin L.A., Jay G., Nelson D.L. The released interleukin-2 receptor binds interleukin 2 efficiently. J. Immunol. 1986; 137: 3841
   PubMed Web of Science ®Google Scholar
• Nelson D.L. Soluble interleukin-2 receptors: analysis in normal individuals and in certain disease states. Fed. Proc. 1986; 45: 377
   Google Scholar
• Wagner D.K., Kiwanuka J., Edwards B.K., Rubin L.A., Nelson D.L., Magrath I.T. Serum Interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: Correlation with survival. J. Clin. Oncol. 1987; 5: 1262
   PubMed Web of Science ®Google Scholar
• Barak V., Ginsburg M., Kalichman I., Polliack A. Serum sIL-2R levels are associated with clinical disease status and pathological grade in non Hodgkin's lymphoma and chronic lymphocytic leukemia. Leukemia and Lymphoma 1992; 7: 431
   PubMed Web of Science ®Google Scholar
• Cornaby A., Simpson M.A., Vann Rice R., Dempsey A., Madras N., Monaco A.P. Interleukin-2 production in plasma and urine, plasma interleukin-2 receptor levels, and urine cytology as a means of monitoring renal allograft recipients. Transplan. Proc. 1988; 20: 108, (Suppl. 1)
   Web of Science ®Google Scholar
• Lawrence E.C., Holland V.A., Young B. Dynamic changes in soluble interleukin-2 receptor levels after lung or heart-lung transplantation. Am. Rev. Respir. Dis. 1989; 140: 789
   PubMed Web of Science ®Google Scholar
• Keshavjee S.H., McRitchie D.I., Rubin L.A., Maurer J., Girotti M., Patterson G.A. The role of soluble interleukin-2 receptor levels in the diagnosis of rejection and infection in lung transplant recipients. Clin. Invest. Med. 1989; 12: B101
   Google Scholar
• Adams D.H., Wang L., Hubscher S.G., Elias E., Neuberger J.M. Soluble interleukin-2 receptors in serum and bile of liver transplant recipients. Lancet 1989; 1: 469
   PubMed Web of Science ®Google Scholar
• Perkins J.D., Munn S.R., Barr D., Ferguson D.C., Carpenter H.A. Evidence that the soluble interleukin 2 receptor level may determine the optimal time for cystoscopically-directed biopsy in pancreaticoduodenal allograft recipients. Transplantation 1990; 49(2)363
   PubMed Web of Science ®Google Scholar
• Brown A.E., Rieder K.T., Webster H.K. Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Am. Rev. Respir. Dis. 1989; 139: 1036–1038
   PubMed Web of Science ®Google Scholar
• Deloron P., Lepers J.P., Coulanges P. Evolution of the levels of soluble interleukin-2 receptors during Plasmodium falciparum and P. vivax malaria. J. Clin. Microbiol. 1989; 27: 1887–1889
   PubMed Web of Science ®Google Scholar
• Meyers J.E., Flournoy N., Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 1986; 153: 478
   PubMed Web of Science ®Google Scholar
• Engelhard D., Or R., Strauss N. Cytomegalovirus infection and disease after T cell depleted allogeneic bone marrow transplantation for malignant hematologic disease. Transplant. Proc 1989; 21: 3101
   PubMed Web of Science ®Google Scholar
• Engelhard D., Marks M.I., Good R.A. Infections in bone marrow transplant recipients. J. Pediat. 1986; 108: 335
   PubMed Web of Science ®Google Scholar
• Ferrara J.L.M., Deeg H.J. Graft versus host disease. N. Engl. J. Med. 1991; 324: 667
   PubMed Web of Science ®Google Scholar
• Siegert W., Josimovic-Alasevic O., Schwerdtfeger R., Baurmann H., Schmidt C.A., Musch R., Schmidt H.J., Hartmann R., Henze G., Huhn D. Soluble interleukin 2 receptors after bone marrow transplantation. Bone Marrow Transplant. 1990; 6(2)97
   PubMed Web of Science ®Google Scholar
• Waldmann H., Polliack A., Hale G. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-I). Lancet 1984; ii: 483
   Google Scholar
• Slavin S., Waldmann H., Or R. Prevention of graft vs host disease in allogeneic bone marrow transplantation for leukemia by T-cell depletion in vitro prior to transplantation. Transplant. Proc. 1985; 17: 465
   Web of Science ®Google Scholar
• Slavin S., Or R., Naparstek E. New approaches for prevention of rejection and graft v host disease (GVHD) in clinical bone marrow transplantation (BMT). Is. J. Med. Sci. 1986; 22: 264
   PubMedGoogle Scholar
• Geist L.J., Monick M.M., Stinski M.F., Hinninghake G.W. The immediate early genes of human cytomegalovirus upregulate expression of the interleukin-2 and interleukin-2 receptor genes. Am. J. Respir. Cell. Mol. Biol. 1991; 5(3)292
   PubMed Web of Science ®Google Scholar